At close: December 20 at 4:00:00 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Cash Flow
-3,467.9840
-4,293.2650
-4,611.7370
-4,142.9150
-2,131.4140
Financing Cash Flow
--
3,143.3610
5,141.3840
3,897.3940
4,601.8160
End Cash Position
1,637.6270
4,203.4880
5,353.3920
4,823.7450
5,069.2660
Interest Paid Supplemental Data
22.5340
16.2330
8.8750
7.4140
3.6740
Issuance of Capital Stock
--
3,137.0390
5,141.3840
3,689.7610
4,601.8160
Free Cash Flow
-3,467.9840
-4,293.2650
-4,611.7370
-4,142.9150
-2,131.4140
12/31/2020 - 11/27/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
NNBP Nanobac Pharmaceuticals, Incorporated
0.0001
0.00%
APLMW Apollomics, Inc.
0.0125
+13.64%
SXTPW 60 Degrees Pharmaceuticals, Inc.
0.0390
-1.27%
NAMSW NewAmsterdam Pharma Company N.V.
14.10
+2.84%
HUMAW Humacyte, Inc.
1.7400
+39.20%
VTVT vTv Therapeutics Inc.
14.96
+3.03%
RVPHW Reviva Pharmaceuticals Holdings, Inc.
0.1375
-8.33%
PTIX Protagenic Therapeutics, Inc.
0.6001
-7.68%
KALV KalVista Pharmaceuticals, Inc.
8.36
+3.34%
APLM Apollomics, Inc.
9.75
+3.72%